5795 related articles for article (PubMed ID: 34831172)
1. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
2. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
3. [Immunity against SARS-CoV-2: walking to the vaccination].
Rodríguez Hernández C; Sanz Moreno L
Rev Esp Quimioter; 2020 Dec; 33(6):392-398. PubMed ID: 32935536
[TBL] [Abstract][Full Text] [Related]
4. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
[TBL] [Abstract][Full Text] [Related]
6. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
7. [Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.].
Lvov DK; Alkhovsky SV; Kolobukhina LV; Burtseva EI
Vopr Virusol; 2020; 65(1):6-15. PubMed ID: 32496715
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.
Ansariniya H; Seifati SM; Zaker E; Zare F
Biomed Res Int; 2021; 2021():8870425. PubMed ID: 33564683
[TBL] [Abstract][Full Text] [Related]
9. An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines.
Al-Sheboul SA; Brown B; Shboul Y; Fricke I; Imarogbe C; Alzoubi KH
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679897
[TBL] [Abstract][Full Text] [Related]
10. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Variants, Vaccines, and Host Immunity.
Mistry P; Barmania F; Mellet J; Peta K; Strydom A; Viljoen IM; James W; Gordon S; Pepper MS
Front Immunol; 2021; 12():809244. PubMed ID: 35046961
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 vaccines and herd immunity: Perspectives, challenges and prospects.
Wong RSY
Malays J Pathol; 2021 Aug; 43(2):203-217. PubMed ID: 34448786
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
14. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
[TBL] [Abstract][Full Text] [Related]
15. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.
Wang Y; Yang C; Song Y; Coleman JR; Stawowczyk M; Tafrova J; Tasker S; Boltz D; Baker R; Garcia L; Seale O; Kushnir A; Wimmer E; Mueller S
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34193524
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
[TBL] [Abstract][Full Text] [Related]
17. Contact-adjusted Immunity Levels against SARS-CoV-2 in Korea and Prospects for Achieving Herd Immunity.
Chun JY; Jeong H; Kim Y
J Korean Med Sci; 2021 Oct; 36(38):e272. PubMed ID: 34609093
[TBL] [Abstract][Full Text] [Related]
18. Promise and challenges in the development of COVID-19 vaccines.
Chen W
Hum Vaccin Immunother; 2020 Nov; 16(11):2604-2608. PubMed ID: 32703069
[TBL] [Abstract][Full Text] [Related]
19. Targets and strategies for vaccine development against SARS-CoV-2.
Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
[TBL] [Abstract][Full Text] [Related]
20. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]